Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXS73565 in Relapsed or Refractory B-cell Malignancies
NCT06980116Phase 1Recruiting
- Sponsor
- Exscientia
- Start
- Mar 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of rec-3565 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL) and 4 more, sponsored by Exscientia. Primary endpoints: Treatment-emergent Adverse Events up to 282 days and Dose-limiting toxicities up to 28 days. Started Mar 2025; status: recruiting.
02
Drugs
rec-3565
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06980116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980116.